CG Oncology, Inc.
Close on Oct 19, 2026
- Market cap
- $5.29B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $1.16M | $-0.90 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 8, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 27, 2026 | Before market open | – | $-0.52 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | Before market open | $1.67M | $-0.57 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 8, 2025 | Before market open | – | $-0.54 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 28, 2025 | Before market open | – | $-0.46 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | $-0.30 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | $-0.28 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | $-0.36 | – |
Press releases
Announcements CG Oncology filed with the SEC
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
Results of operations · Other events · EX-99.1 to Form 8-K
CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Attacking Bladder Cancer for a Better Tomorrow
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Attacking Bladder Cancer for a Better Tomorrow
Regulation FD disclosure · EX-99.1 to Form 8-K
CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND -003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K